Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24132
Title: Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question
Authors: BURZYKOWSKI, Tomasz 
Saad, Everardo D.
BUYSE, Marc 
Issue Date: 2017
Publisher: AMER MEDICAL ASSOC
Source: JAMA ONCOLOGY, 3(3), p. 416-416
Notes: [Burzykowski, Tomasz; Saad, Everardo D.] Int Inst Drug Dev, 30 Ave Provinciale, B-1340 Louvain La Neuve, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Hasselt, Belgium. [Saad, Everardo D.] Dendrix Res, Sao Paulo, Brazil. [Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA.
Document URI: http://hdl.handle.net/1942/24132
ISSN: 2374-2437
e-ISSN: 2374-2445
DOI: 10.1001/jamaoncol.2016.3941
ISI #: 000397491400023
Rights: (c) 2017 American Medical Association. All rights reserved.
Category: A1
Type: Journal Contribution
Validations: ecoom 2018
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
burzykowski2016.pdfPublished version36.91 kBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.